HVTN705
The primary purpose is to assess the efficacy, safety, and tolerability of a heterologous prime/boost regimen utilizing Ad26.Mos4.HIV and aluminum-phosphate adjuvanted Clade C gp 140 for the prevention of HIV infection in HIV-seronegative women residing in sub-Saharan Africa
More text
Sponsored By:
HIV Vaccine Trials NetworkPrincipal Investigator:
William Kilembe, Mubiana InambaoPosted:
18/10/2023 | 2 years ago